An interventional study of Zirconia-fortified glass ionomer and Resin-modified glass ionomer in Dental Caries, sponsored by Cairo University. Not yet recruiting at 1 site in Egypt. Open to participants aged 4 Years to 7 Years. Per ClinicalTrials.gov, last updated 2026-08-28.
Sponsored by Cairo University · Not applicable, Interventional, and Treatment
Among 151 studies in Dental Caries by Cairo University — 41 open to participants now, 43 under way, none of them phase 3. Dental Caries · Cairo University.
Among the 151 studies in Dental Caries by Cairo University, this one is the 43rd largest by planned enrollment of the 120 interventional ones that give a count, is one of 11 that started in 2026, is one of 101 with no phase, reaches primary completion later than 41 of the 42 other live ones, and was the 148th registered.
1,171 studies on the registry are indexed under Dental Caries; 209 are open to participants now.
Browse Dental Caries studies →41 of the 151 studies in Dental Caries by Cairo University are open now, in 1 country. Recruiting first, the newest first:
Cairo University · Sites in Egypt
Cairo University · Sites in Egypt
Cairo University · Sites in Egypt
Cairo University · Sites in Egypt
Cairo University
By country, each count listing its studies:
Of the 86 Dental Caries studies recruiting now, 18 (21%) set no upper age limit and 66 (77%) stop at 75 or younger; 60 take children under 18; 53 take healthy volunteers.
This study: 4 Years to 7 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
151 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 4 · Phase 3 5 · Phase 4 6
First in 2015; this study’s year is marked. 11 started in 2026.
This study's planned enrollment of 50 is below the median of 60 across 967 interventional studies indexed under Dental Caries.
Median enrollment 46 across the 120 interventional studies, 250 across the 31 observational. Of the 40 that completed or were terminated, 1 (3%) have results posted.
This tab as a report to print or save as PDF → With an account.
Cairo University is the lead sponsor of 4,941 studies on the registry; 1,458 are open to participants now.
Of its 37 completed or terminated interventional studies of FDA-regulated products, 5 (14%) have results posted.
13 of the studies in Dental Caries by Cairo University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07612540Cairo UniversityRetention and Caries Prevention of Giomer Sealant With or Without Diode Laser Pre-treatment: A Randomized Controlled Trial | 2026-12-01 |
| NCT07171775Cairo UniversityThis Study Aims to Clinically Assess and Radiographically Measure the Formed Dentin Bridge Over the Pulp, Utilizing Three-dimensional Imaging Following the Application of a Bioactive Restorative System Versus a Conventional Restorative System After Selective Caries Removal to Soft Dentin Over 2 | 2026-12-01 |
| NCT06780527Cairo UniversityClinical Performance of Resin Composite Restoration After Dentin Biomodification by Grape Seed Extract in Deep Carious Lesions. | 2026-12-01 |
| NCT06497231Cairo UniversityEvaluation of Bioactive Giomer Material Versus Nanohybrid Resin Composite in Deep Marginal Elevation | 2026-12-01 |
| NCT06901453Cairo UniversityThe Effectiveness RMGI and Giomer, Individually and Combined Anterior Cervical Caries | 2026-12-31 |
Among the 151 studies in Dental Caries by Cairo University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Clinical trial comparing two tooth-colored restorative materials for treating cavities between the teeth of primary molars in children aged 4 to 7 years. The study will compare zirconia-fortified glass ionomer (Zirconomer-P) with resin-modified glass ionomer (RMGI) to evaluate their clinical performance, including the condition of the restoration, marginal adaptation, proximal contact, occlusion, wear, fracture, retention, and development of caries at the restoration margin. Children will be followed for up to 18 months after treatment.
This randomized clinical trial will evaluate the clinical performance of zirconia-fortified glass ionomer (Zirconomer-P capsules) compared with resin-modified glass ionomer (FX-Ultra) for restoring proximal cavities in primary molars.
The study will include children aged 4 to 7 years with posterior primary molars having proximal carious lesions classified as International Caries Detection and Assessment System (ICDAS) 3 or 4, with no clinical or radiographic signs of pulpal involvement. Eligible participants will be randomly allocated to receive either zirconia-fortified glass ionomer or resin-modified glass ionomer as the restorative material.
The restorative procedure will include dental prophylaxis, isolation of the operative field, selective removal of carious tissue, cavity preparation, placement of a matrix and wedge, and restoration using the assigned material. Local anesthesia will not be routinely administered according to the study protocol.
The primary outcome will assess the biological properties of the restorations, including caries at the restoration margin, dental hard tissue defects at the restoration margin, and postoperative hypersensitivity or pulp status. Secondary outcomes will assess functional properties, including marginal adaptation, proximal contact point, form and contour, occlusion and occlusal wear, fracture of the restorative material, and retention.
Clinical outcomes will be assessed using the revised Fédération Dentaire Internationale (FDI) criteria. Participants will be evaluated at baseline and during follow-up visits at 3, 6, 12, and 18 months after restoration. Outcome assessment will be performed by the study assessors, with calibration and assessment of inter- and intra-observer agreement before the study begins.
The study is designed to determine whether zirconia-fortified glass ionomer provides comparable or superior clinical performance to resin-modified glass ionomer for proximal restorations in primary molars over an 18-month follow-up period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants assigned to this arm will receive zirconia-fortified glass ionomer (Zirconomer-P capsules) for restoration of proximal cavities in primary molars.
Combination Product: Zirconia-fortified glass ionomer
Participants assigned to this arm will receive resin-modified glass ionomer (FX-Ultra) for restoration of proximal cavities in primary molars.
Combination Product: Resin-modified glass ionomer
Zirconia-fortified glass ionomer (Zirconomer-P capsules) will be used to restore proximal carious cavities in primary molars. The material will be placed after selective removal of carious tissue and cavity preparation. Restorations will be clinically evaluated at baseline and at 3, 6, 12, and 18 months using the revised FDI criteria.
Also known as: Zirconomer-P
Resin-modified glass ionomer (FX-Ultra) will be used as the restorative material for proximal carious cavities in primary molars. The material will be applied to the gingival seat and packed into the prepared cavity using a gold-plated applicator. Participants will be followed at baseline and at 3, 6, 12, and 18 months for clinical evaluation of the restoration.
Also known as: FX-Ultra
Biological Properties of Restorations According to the Revised FDI Criteria
Assessment of biological properties of the restorations, including caries at the restoration margin, dental hard tissue defects at the restoration margin, and postoperative hypersensitivity/pulp status using the revised Fédération Dentaire Internationale (FDI) criteria.
Time frame: Baseline, 3, 6, 12, and 18 months after restoration
Functional Properties of Restorations According to the Revised FDI Criteria
Assessment of the functional properties of the restorations, including marginal adaptation, proximal contact point, form and contour, occlusion and occlusal wear, fracture of the restorative material, and retention, using the revised Fédération Dentaire Internationale (FDI) criteria.
Time frame: Baseline, 3, 6, 12, and 18 months after restoration
Plan to share: Undecided — The plan for sharing individual participant data (IPD) with other researchers has not yet been determined. Any future data sharing will be considered in accordance with applicable ethical, privacy, and institutional requirements
No publications or documents are linked to this record.
Start is estimated for Sep 2026; primary completion for Mar 2028, 18 months later.
Of 469 non-industry interventional studies with no phase under Dental Caries, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 30. This study's planned 18 months is above that.
Counting every sponsor, half of 502 studies reached it within 15 months; a quarter within 7 and three quarters within 29.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.